

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Guideline scope update

### Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

This is an update of the NICE guideline on diabetes (type 1 and type 2) in children and young people (NG18). The update will look at medicines that can be used in combination with metformin, or if metformin is not tolerated, for treatment of type 2 diabetes.

The update will be developed using the methods and processes outlined in [developing NICE guidelines: the manual](#).

This update may also be used to update the [NICE quality standard for diabetes in children and young people](#).

#### 1 Why the update is needed

New evidence that could affect recommendations was identified through the surveillance process. Topic experts, including those who helped to develop the existing guideline, advised NICE on whether areas should be updated or new areas added. Full details are set out in the [surveillance review decision](#).

#### 2 Who the update is for

This guideline is for:

- healthcare professionals who care for children and young people with type 2 diabetes
- commissioners and providers of NHS-funded healthcare services
- children and young people with type 2 diabetes, and their families and carers

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#) and [Northern Ireland Executive](#).

Diabetes (type 1 and type 2) in children and young people: NICE guideline DRAFT (March 2022)

## 1 **Equality considerations**

2 NICE has carried out an [equality impact assessment](#) during scoping. The  
3 assessment:

- 4 • lists equality issues identified, and how they have been addressed
- 5 • explains why any groups are excluded from the scope.

6 The guideline will consider inequalities relating to age, disability, race, ethnicity,  
7 religion and belief.

## 8 **3 What the update will cover**

### 9 **3.1 Who is the focus?**

#### 10 **Groups that will be covered**

- 11 • Children and young people aged under 18 with type 2 diabetes.

### 12 **3.2 Settings**

#### 13 **Settings that will be covered**

- 14 • All settings where NHS care is provided.

### 15 **3.3 Activities, services or aspects of care**

#### 16 **Key area that will be covered in this update**

17 We will look at evidence in the area below when developing this update. We will  
18 consider making new recommendations or updating existing recommendations in  
19 this area only.

20 1 Medicines that can be used in combination with metformin, or if metformin is  
21 not tolerated, for treatment of type 2 diabetes in children and young people

22

23 Note that guideline recommendations for medicines will normally fall within licensed  
24 indications; exceptionally, and only if clearly supported by evidence, use outside a  
25 licensed indication may be recommended. The guideline will assume that prescribers

1 will use a medicine's summary of product characteristics to inform decisions made  
2 with individual patients.

### 3 **Changes to the guideline**

4 For the [section on metformin for children and young people with type 2 diabetes](#), we  
5 will review the evidence for medicines that can be used in combination with  
6 metformin, or if metformin is not tolerated, and consider making new  
7 recommendations or updating the existing recommendation.

8 For all other sections of the guideline, there will be no evidence review and we will  
9 retain the existing recommendations.

10 Recommendations in areas that are being retained may be edited to ensure that they  
11 meet current editorial standards, and reflect the current policy and practice context.

### 12 **Related NICE guidance**

#### 13 **Published**

- 14 • [Type 2 diabetes in adults: management](#) (2022) NICE guideline NG28
- 15 • [Babies, children and young people's experience of healthcare](#) (2021) NICE  
16 guideline NG204
- 17 • [Diabetic foot problems: prevention and management](#) (2015) NICE guideline NG20
- 18 • [Type 2 diabetes: prevention in people at high risk](#) (2012) NICE guideline PH38
- 19 • [Type 2 diabetes prevention: population and community-level interventions](#) (2011)  
20 NICE guideline PH35
- 21 • [Physical activity for children and young people](#) (2009) NICE guideline PH17
- 22 • [Obesity prevention](#) (2006) NICE guideline CG43
- 23 • [Dental checks: intervals between oral health reviews](#) (2004) NICE clinical  
24 guideline CG19

#### 25 **In development**

- 26 • [Dulaglutide for treating type 2 diabetes](#) [ID1451]. NICE technology appraisal  
27 guidance. Publication date to be confirmed.
- 28 • [Semaglutide for treating type 2 diabetes](#) [ID1450]. NICE technology appraisal  
29 guidance. Publication date to be confirmed.

- 1 • [Sotagiflozin for treating type 2 diabetes](#) [ID1657]. NICE technology appraisal  
2 guidance. Publication date to be confirmed.
- 3 • [Tirzepatide for treating type 2 diabetes](#) [ID3938]. NICE technology appraisal  
4 guidance. Publication date to be confirmed.

### 5 **NICE guidance about the experience of people using NHS services**

6 NICE has produced the following guidance on the experience of people using the  
7 NHS. This guideline will not include additional recommendations on these topics  
8 unless there are specific issues related to type 2 diabetes in children and young  
9 people.

- 10 • [Shared decision making](#) (2021) NICE guideline NG197
- 11 • [Medicines optimisation](#) (2015) NICE guideline NG5
- 12 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 13 • [Service user experience in adult mental health](#) (2011) NICE guideline CG136
- 14 • [Medicines adherence](#) (2009) NICE guideline CG76

### 15 **3.4 Economic aspects**

16 We will take economic aspects into account when making recommendations. We will  
17 develop an economic plan that states for each review question (or key area in the  
18 scope) whether economic considerations are relevant, and if so whether this is an  
19 area that should be prioritised for economic modelling and analysis. We will review  
20 the economic evidence and carry out economic analyses, using a NHS, public sector  
21 and other perspectives, as appropriate.

### 22 **3.5 Key issues and draft questions**

23 While writing the scope for this updated guideline, we have identified the following  
24 key issue and draft question related to it:

- 25 1 Treatment for type 2 diabetes in children and young people
  - 26 1.1 What is the clinical effectiveness, cost effectiveness and acceptability  
27 of pharmacological treatments in combination with metformin, or if  
28 metformin is not tolerated, for improving glycaemic control in children and

1 young people with type 2 diabetes compared with usual care (metformin  
2 alone)?

3 The key issue and draft question will be used to develop more detailed review  
4 questions, which guide the systematic review of the literature.

### 5 **3.6 Main outcomes**

6 The main outcomes that may be considered when searching for and assessing the  
7 evidence are:

- 8 • glycaemic control
- 9 • any adverse effects of the medicines used
- 10 • health-related quality of life (assessed by validated questionnaire), for example a  
11 diabetes-specific health-related quality of life
- 12 • complications of diabetes
- 13 • mortality
- 14 • psychological outcomes
- 15 • patient satisfaction
- 16 • intermediate outcomes (including disease management goals such as blood  
17 pressure, lipid profile and BMI)
- 18 • use of health services (including hospitalisation, A&E attendance, and financial  
19 barriers to care)
- 20 • patient-reported outcomes (including psychological well-being [WHO-5], diabetes  
21 distress [PAID], depression [PHQ-9], and activities of daily living).

## 22 **4 NICE quality standards**

23 **NICE quality standards that may need to be revised or updated when this**  
24 **guideline is published**

- 25 • [Diabetes in children and young people](#) (2016) NICE quality standard 125.

26

## 1 Further information

This is the draft scope for consultation with registered stakeholders. The consultation dates are 18th March to 14th April 2022.

You can [follow progress of the guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

2 © NICE 2022. Subject to [Notice of rights](#).